Expertise in
16
conditions

Dr. Peter A. Mcsweeney

Hematology Oncology
1721 E 19th Ave Ste 300, 
Denver, CO 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
16
conditions
1721 E 19th Ave Ste 300, 
Denver, CO 

Overview

Peter Mcsweeney is a Hematologist Oncology provider in Denver, Colorado. Dr. Mcsweeney is highly rated in 16 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Licenses

Internal Medicine in CO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1721 E 19th Ave Ste 300, Denver, CO 80218

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 19, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Dexamethasone
Study Phase: Phase 2
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: July 14, 2025
Intervention Type: Biological
Study Drugs: AUTO3, cyclophosphamide, fludarabine, pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2024
Intervention Type: Biological
Study Drug: NKX019
Study Phase: Phase 1
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 17, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
Improved Behavioral Outcome in Allogeneic Hematopoietic Stem Cell Transplant Patients by Reducing Caregiver Distress: Behavioral and Physiological Evidence
Improved Behavioral Outcome in Allogeneic Hematopoietic Stem Cell Transplant Patients by Reducing Caregiver Distress: Behavioral and Physiological Evidence
Enrollment Status: Completed
Publish Date: December 06, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 8 Less Clinical Trials

31 Total Publications

Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
Journal: Bone marrow transplantation
Published: August 18, 2023
Similar Doctors
Laurie L. Carr
Expertise in
13
conditions
Dr. Laurie L. Carr
Hematology Oncology | Oncology
Expertise in
13
conditions
Dr. Laurie L. Carr
Hematology Oncology | Oncology

National Jewish Health

1400 Jackson Street, Division Of Oncology, 
Denver, CO 
 (1.7 miles away)
303-388-4461
Experience:
26+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Laurie Carr is a Hematologist Oncology specialist and an Oncologist in Denver, Colorado. Dr. Carr has been practicing medicine for over 26 years is highly rated in 13 conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and ALK-Positive Non-Small Cell Lung Cancer. Dr. Carr is currently accepting new patients.

Expertise in
16
conditions
Dr. Ryan M. Weight
Hematology Oncology
Expertise in
16
conditions
Dr. Ryan M. Weight
Hematology Oncology

Saint Joseph Hospital - Cancer Centers Of Colorado

1825 North Marion Street, 
Denver, CO 
 (1.0 miles away)
303-318-3434
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ryan Weight is a Hematologist Oncology provider in Denver, Colorado. Dr. Weight has been practicing medicine for over 16 years is highly rated in 16 conditions, according to our data. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Melanoma of the Eye, and Squamous Cell Lung Carcinoma. Dr. Weight is currently accepting new patients.

Expertise in
40
conditions
Dr. Anthony D. Accurso
Hematology Oncology | Hematology | Oncology
Expertise in
40
conditions
Dr. Anthony D. Accurso
Hematology Oncology | Hematology | Oncology

Good Samaritan Hospital - Cancer Centers Of Colorado

340 Exempla Circle, 
Lafayette, CO 
 (20.6 miles away)
303-673-1944
Experience:
14+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Accurso is a Hematologist Oncology specialist and a Hematologist in Lafayette, Colorado. Dr. Accurso has been practicing medicine for over 14 years is highly rated in 40 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Large-Cell Immunoblastic Lymphoma, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Peter A. Mcsweeney

How do I make an appointment with Dr. Peter A. Mcsweeney?

You can book an appointment with Dr. Peter A. Mcsweeney by calling their office at 720-754-4800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Peter A. Mcsweeney a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Peter A. Mcsweeney is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Peter A. Mcsweeney specialize in?

While Dr. Peter A. Mcsweeney is a Hematology Oncology, they have specific expertise in Acute Myeloid Leukemia (AML), Multiple Myeloma, and Acute Myeloblastic Leukemia without Maturation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Peter A. Mcsweeney participate in research or clinical trials?

Yes. Dr. Peter A. Mcsweeney has published 31 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Peter A. Mcsweeney's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Peter A. Mcsweeney accept my insurance?

Dr. Peter A. Mcsweeney accepts most major insurance plans, including Humana and UnitedHealthcare. We recommend calling the office directly at 720-754-4800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcsweeney's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile